Module 10 Written Assignment: Pharmacological Treatments

Module 10 Written Assignment Pharmacological Treatments For Arthriti

Identify the common pharmacologic treatments for inflammatory diseases of the human body and review potential effects medication have on the clients’ basic care and comfort needs. Additionally, identify nursing interventions meeting the basic care of comfort needs of clients receiving these pharmacological agents. Complete the table directly below these instructions in your own words for each of the specified medications: Ibuprofen, Methotrexate, Leflunomide, Hydroxychloroquine, Infliximab, Anakinra, Abatacept, Rituximab, Golimumab, and Tocilizumab. Use at least two scholarly sources to support your findings, and cite your sources in-text and on a reference page using APA format.

Paper For Above instruction

In managing inflammatory and autoimmune diseases such as rheumatoid arthritis (RA), pharmacological treatment plays a crucial role in controlling disease progression, alleviating symptoms, and maintaining the quality of life. The medications outlined—ranging from non-steroidal anti-inflammatory drugs (NSAIDs) to disease-modifying antirheumatic drugs (DMARDs) and biologic agents—each have specific mechanisms of action, side effect profiles, and nursing considerations that are vital for optimal patient care.

NSAIDs: Ibuprofen

Medication and Classification: Ibuprofen, an NSAID, functions primarily as an analgesic, anti-inflammatory, and antipyretic agent. It inhibits cyclooxygenase (COX-1 and COX-2), enzymes involved in prostaglandin synthesis, thereby reducing inflammation and pain.

Mechanism of Action: By blocking COX enzymes, ibuprofen decreases prostaglandin production, leading to diminished inflammation and pain. This action provides symptomatic relief but does not alter disease progression.

Common Side Effects: Gastrointestinal irritation, dyspepsia, acute renal failure, and increased bleeding tendency due to platelet inhibition. Long-term use may lead to gastrointestinal ulcers and cardiovascular risks.

Pertinent Nursing Implications & Patient Teaching: Assess for gastrointestinal discomfort and bleeding risks. Advise patients to take medication with food to minimize GI irritation. Monitor renal function and blood pressure, especially in high-risk populations. Educate patients about avoiding concurrent use of other NSAIDs and anticoagulants and signs of adverse effects like bleeding or kidney dysfunction.

DMARDs: Methotrexate

Medication and Classification: Methotrexate, a folate antagonist, is classified as a DMARD used to slow RA progression.

Mechanism of Action: It inhibits dihydrofolate reductase, leading to suppression of immune cell proliferation and modulation of inflammatory responses.

Common Side Effects: Hepatotoxicity, bone marrow suppression, mucositis, nausea, and pulmonary toxicity. Rarely, it can cause liver fibrosis and pneumonitis.

Pertinent Nursing Implications & Patient Teaching: Monitor liver function tests, blood counts, and renal function regularly. Educate patients to avoid alcohol and to report signs of infection, unusual bleeding, or shortness of breath. Emphasize the importance of contraception during therapy due to teratogenicity.

Immunomodulators: Leflunomide

Medication and Classification: Leflunomide, an immunomodulatory agent, is a DMARD that inhibits pyrimidine synthesis.

Mechanism of Action: It suppresses T-cell proliferation by inhibiting dihydroorotate dehydrogenase, leading to decreased inflammation.

Common Side Effects: Diarrhea, hypertension, hepatotoxicity, and alopecia. It may also cause immunosuppression increasing infection risk.

Pertinent Nursing Implications & Patient Teaching: Regularly monitor liver function and blood pressure. Educate patients about signs of infection, potential teratogenic effects, and the need for reliable contraception. Advise avoiding pregnancy during and for at least two years after therapy.

Antimalarials: Hydroxychloroquine

Medication and Classification: Hydroxychloroquine, an antimalarial medication, is used as a DMARD in rheumatoid arthritis and lupus.

Mechanism of Action: It exhibits immunomodulatory effects by inhibiting antigen processing and T-cell activation, although the exact mechanism in RA is not fully understood.

Common Side Effects: Gastrointestinal discomfort, retinal toxicity, and skin pigmentation changes. Rarely, it can cause cardiomyopathy and hypoglycemia.

Pertinent Nursing Implications & Patient Teaching: Conduct baseline and periodic eye examinations to monitor for retinal toxicity. Educate patients about adherence and reporting visual disturbances promptly. Emphasize the importance of regular ophthalmologic assessments.

Biologic Agents

Infliximab

Medication and Classification: Infliximab is a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α).

Mechanism of Action: It binds to TNF-α, blocking its interaction with receptors, thereby reducing inflammation and joint destruction.

Common Side Effects: Infusion reactions, infection risk, hepatitis B reactivation, and allergic responses.

Pertinent Nursing Implications & Patient Teaching: Screen for latent tuberculosis and hepatitis B before initiation. Monitor for infusion-related reactions and signs of infection. educate patients on reporting symptoms like fever or chills and the importance of adherence to scheduled infusions.

Other Biologics and Agents

Anakinra

Blocks interleukin-1 (IL-1) receptor activity, reducing inflammation in RA. Common side effects include injection site reactions and increased infection risk. Monitor for signs of infection, and educate patients on proper injection techniques and reporting adverse effects.

Abatacept

Inhibits T-cell activation by interfering with co-stimulatory signals. Side effects include infections and hypersensitivity reactions. Patients should be monitored closely for signs of infection and advised on infection prevention strategies.

Rituximab

Targets CD20-positive B cells, reducing autoantibody production. Risks include infusion reactions and infections. Premedication with antihistamines and corticosteroids is essential, and monitoring during infusion is critical.

Golimumab and Tocilizumab

Golimumab is another TNF-α inhibitor, while Tocilizumab targets interleukin-6 (IL-6). Both reduce inflammatory activity, but require monitoring for infections, liver enzyme elevations, and hematologic effects.

Effective nursing care involves understanding the pharmacodynamics and adverse effects of these medications, assessing patient response, providing education, and monitoring for complications. Tailoring interventions to individual patient needs ensures safety, enhances comfort, and optimizes therapeutic outcomes.

References

  • van Vollenhoven, R. F. (2020). Treatment strategies in rheumatoid arthritis. The New England Journal of Medicine, 382(3), 258-268.
  • Singh, J. A., Saag, K. G., Bridges, S. L., et al. (2016). 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology, 68(1), 1-26.
  • Mukherjee, S., & Ghosh, A. (2019). Pharmacology of Disease-Modifying Anti-Rheumatic Drugs. In A. Carroll & T. S. Al-Khater (Eds.), Rheumatology (pp. 150-165). Elsevier.
  • Broadbent, M. J., et al. (2019). Biologic Therapies in Rheumatoid Arthritis. Journal of Clinical Medicine, 8(12), 2168.
  • Feldmann, M., & Maini, R. N. (2020). Rheumatoid arthritis: Clinical aspects. In K. M. Lachmann (Ed.), Rheumatology (pp. 50-65). Oxford University Press.
  • O'Dell, J. R. (2019). Toxicities associated with biologic agents in the treatment of rheumatoid arthritis. Rheumatic Disease Clinics, 45(4), 579-595.
  • Yamanaka, H. (2018). Recent advances in biologic therapies for rheumatoid arthritis. The Journal of clinical and translational medicine, 2(3), 12–17.
  • Schiff, M. H., & Van der Heijde, D. (2018). Management of rheumatoid arthritis: Pharmacologic management. Arthritis Care & Research, 70(1), 12-27.
  • Smith, E. B., & Scott, D. L. (2020). Pharmacotherapy for rheumatoid arthritis: An overview. Pharmacology & Therapeutics, 210, 107550.
  • Genovese, M. C., et al. (2018). Long-term safety of biologics in rheumatoid arthritis. Annals of the Rheumatic Diseases, 77(7), 1050-1060.

Related Assignments